Skye Bioscience, Inc. (SKYE)
|52 Week Range||0.011-0.069|
|1y Target Est||-|
|DCF Unlevered||SKYE DCF ->|
|DCF Levered||SKYE LDCF ->|
|Debt / Equity||-187.33%||Sell|
Upgrades & Downgrades
Latest SKYE news
Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
22 November 2022
San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid de...
Skye Bioscience submits IND application for SBI-100 Ophthalmic Emulsion to US regulator
17 November 2022
Skye Bioscience Inc (OTCQB:SKYE) said it has submitted an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its SBI-100 Ophthalmic Emulsion (SBI-100 OE), whic...
Skye Bioscience recruits patients for first cohort in trial to treat glaucoma with ophthalmic drug
16 November 2022
Skye Bioscience Inc (OTCQB:SKYE) said it has started screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion (SBI-100 OE), a proprietary, synthetic cannabinoid derivative intende...
Skye Bioscience concludes merger with Emerald Health Therapeutics and unveils goals for 2022 and 202...
11 November 2022
Skye Bioscience Inc (OTCQB:SKYE) announced that it has concluded the merger with Emerald Health Therapeutics after both companies' shareholders voted in favor and the Supreme Court of British Columbia...
Skye Bioscience completes drug production for phase one clinical study using synthetic cannabinoids ...
20 September 2022
Skye Bioscience Inc (OTCQB:SKYE) said it has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (SBI-100 OE) for Skye's phase one clinical tr...
Skye Bioscience says Emerald Health Therapeutics shareholders approve integration plan of arrangemen...
22 August 2022
Skye Bioscience Inc (OTCQB:SKYE) has announced that the shareholders of Emerald Health Therapeutics Inc (CSE:EMH, OTCQX:EMHTF) have approved the proposed plan of arrangement which will result in the i...
Skye Bioscience selects NextPharma as phase 2 contract drug manufacturer
21 July 2022
Skye Bioscience Inc (OTCQB:SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, said it has selected NextPharma as its contract manufacturing o...
Skye Bioscience reports slight delay in the production of its Phase 1 drug to treat glaucoma
20 July 2022
Skye Bioscience inc (OTCQB:SKYE) said completion of the production of its Phase 1 drug has been delayed to the beginning of September 2022 due to a now resolved cyber-attack and planned maintenance sh...
Skye Bioscience gets regulatory approval for first-in-human Phase 1 clinical study of patented drug ...
30 June 2022
Skye Bioscience inc (OTCQB:SKYE) has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion, a patented drug representing a new class of therape...
Skye Bioscience is primed for meaningful clinical development of cannabinoid-derivative drug SBI-100...
28 June 2022
Small companies accessing capital to fund growth mostly have an uphill challenge. With inflation slamming the global economy like a wrecking ball this year, the market mayhem is going to make it even ...